Other languages Nuformix plc

Equities

Delayed London S.E. Other stock markets 05:51:26 2024-05-03 am EDT			5-day change	1st Jan Change
0.179 ^GBX	-3.24%		-12.68%	-44.92%

Mar. 01	Nuformix announces subscription to raise GBP150,000	AN
Jan. 15	Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	CI

Nuformix announces subscription to raise GBP150,000	Mar. 01
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	Jan. 15
Nuformix narrows annual loss as develops drug assets	Jan. 03
Nuformix plc Reports Earnings Results for the Half Year Ended September 30, 2023	Jan. 03
Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002	23-10-23
Nuformix Receives Japanese Patent for Pulmonary Fibrosis Treatment; Shares Surge	23-10-23
Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan	23-10-23
Nuformix Updates Oxilio Agreement for NXP001	23-09-18
Nuformix to receive milestone payments from Oxilio pact	23-09-18
Nuformix plc Receives New NXP001 Development Milestone Payments in Updated Oxilio Agreement	23-09-18
Nuformix loss narrows; near-term goal to focus on NXP002 asset	23-05-22
Nuformix plc Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-22
Nuformix says NXP002 shows anti-inflammatory effect	23-05-18
Nuformix to Launch Partnering Process for Inhaled Lung Disease Drug	23-05-18
Nuformix plc Announces Update Regarding the NXP002 Programme	23-05-18
Nuformix raises GBP70,000 to fund NXP002 programme	23-04-17
Nuformix Plans Equity Raise to Fund Inhaled Treatment Program; Shares Sink 18%	23-04-17
Sabien works with Empiric; Coro sells in Italy	23-03-27
Nuformix plc Announces the Update Regarding the Company's Nxp002 Programme	23-03-27
Nuformix plc Announces Changes to Financial Year End from 31 March to 30 September	23-03-13

No results for this search